This webinar took place on June 9, 2020.

Description: Womble Bond Dickinson Healthcare Regulatory attorney Toni Peck presented on “Where Do We Stand (or Fall): An Evaluation of Trends in Drug Cost Transparency and 340B Pricing Program Legislation” at an Association of Corporate Counsel Greater Philadelphia Chapter webinar.

With the stated objective of lowering drug prices and increasing transparency, many state governments have enacted drug costs transparency laws. Simultaneously, both state and federal governments have introduced and enacted legislation aimed at the 340B Drug Pricing Program. Peck joined Teva General Counsel Brian Savage in a discussion of these topics and trends.

Please click here for more information about the ACC Virtual Health, Biotech & Pharma CLE Institute.

Toni Peck’s practice is focused on assisting healthcare providers in a variety of corporate transactions and regulatory compliance matters. She regularly advises healthcare systems, academic medical centers, large physician practices, and other health care providers on mergers and acquisitions, joint ventures, and other strategic alignments and complex affiliations. Ms. Peck also regularly advises her clients on regulatory compliance matters, including 340B Drug Pricing Program and fraud and abuse issues such as the Stark Law and Anti-Kickback Statute. She also advises health care providers on day-to-day operations and governance matters, including risk management and compliance issues.